{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"38.3","upperLimit":"50.1","value":"44.1"},{"groupId":"OG001","lowerLimit":"9.2","upperLimit":"21.3","value":"14.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"290"},{"groupId":"OG001","value":"145"}],"units":"Participants"}],"description":"DCR was defined as the proportion of participants with a best overall response of complete response (CR), partial response (PR), or stable disease (SD). The assessment of DCR was based on Investigator review of radiologic images and following RECIST criteria (version 1.1, 2009).","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received 35 mg/m\\^2 of TAS-102 tablets orally BID for 5 days per week (i.e., from Days 1 to 5 and Days 8 to 12) for 2 weeks followed by 14 days rest in each 28-day cycle along with BSC until a discontinuation criterion (participant withdrawal, disease progression, irreversible treatment-related Grade 4 non-hematologic event, physician's decision, pregnancy or death) was met.","id":"OG000","title":"TAS-102+BSC"},{"description":"Participants received 35 mg/m\\^2 of matching placebo for TAS-102 tablets orally BID for 5 days per week (i.e., from Days 1 to 5 and Days 8 to 12) for 2 weeks followed by 14 days rest in each 28-day cycle along with BSC until discontinuation criterion (participant withdrawal, disease progression, irreversible treatment-related Grade 4 non-hematologic event, physician's decision, pregnancy or death) was met.","id":"OG001","title":"Placebo+BSC"}],"paramType":"NUMBER","populationDescription":"Analysis was performed on TR population that included participants in the ITT population that met 2 criteria: had measurable disease (at least 1 target lesion) at baseline; had at least 1 post-baseline evaluation or early disease progression/cancer-related death occurred before first evaluation on treatment (post-baseline).","reportingStatus":"POSTED","timeFrame":"From the date of randomization to the cut-off date (maximum duration: up to approximately 46 months), assessed every 8 weeks","title":"Disease Control Rate (DCR)","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"percentage of participants"}